COLUMBUS研究:encorafenib联合binimetinib的不良事件发生率、病程与管理
COLUMBUS研究纳入570例BRAFV600突变晚期黑色素瘤患者,随机接受encorafenib+binimetinib、encorafenib或vemurafenib治疗。encorafenib+binimetinib组常见BRAFi/MEKi毒性总体可控、可逆且停药率低;发热和光敏反应发生率低于vemurafenib,但浆液性视网膜病变发生率较高(20% vs 2%),无患者因此停药。
要点
- encorafenib+binimetinib组发热发生率18%,低于vemurafenib的30%,且首次发生时间较晚(中位85天)。
- encorafenib+binimetinib组光敏反应发生率5%,低于vemurafenib的30%。
- encorafenib+binimetinib组浆液性视网膜病变发生率20%,高于encorafenib和vemurafenib的2%,但无患者因此停药。
核心结论
- encorafenib+binimetinib在BRAFV600突变黑色素瘤患者中总体耐受性良好,停药率低,安全性特征与其他抗BRAF/MEK靶向治疗不同。
研究设计与样本
- COLUMBUS研究为随机对照试验,纳入局部晚期、不可切除或转移性BRAFV600突变黑色素瘤患者。
- 患者随机接受encorafenib 450 mg每日一次联合binimetinib 45 mg每日两次、encorafenib 300 mg每日一次或vemurafenib 960 mg每日两次治疗。
- 安全性人群共570例:encorafenib+binimetinib组192例,encorafenib组192例,vemurafenib组186例。
主要发现
- encorafenib+binimetinib组中位暴露时间长于encorafenib组和vemurafenib组(51周 vs 31周 vs 27周)。
- encorafenib+binimetinib组常见BRAFi/MEKi毒性一般可控、可逆,且与停药不常相关。
- encorafenib+binimetinib组发热发生率为18%,encorafenib组为16%,vemurafenib组为30%;encorafenib+binimetinib组首次发热中位时间为85天,encorafenib组为2.5天,vemurafenib组为19天。
- encorafenib+binimetinib组光敏反应发生率为5%,encorafenib组为4%,vemurafenib组为30%。
- encorafenib+binimetinib组浆液性视网膜病变发生率为20%,encorafenib组和vemurafenib组均为2%,但无患者因该事件停用encorafenib+binimetinib。
临床怎么用
- encorafenib+binimetinib治疗期间需关注浆液性视网膜病变,尽管其发生率较高但通常无需停药。
- 发热和光敏反应在encorafenib+binimetinib治疗中发生率较低,且发热出现较晚,临床监测策略可相应调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dual inhibition of the mitogen-activated protein kinase pathway with BRAF/MEK inhibitor (BRAFi/MEKi) therapy is a standard treatment for BRAFV600-mutant metastatic melanoma and has historically been associated with grade III pyrexia or photosensitivity depending on the combination used. The objective of this study was to fully describe adverse events from the COLUMBUS study evaluating the most recent BRAF/MEK inhibitor combination encorafenib+binimetinib. PATIENTS AND METHODS: Patients with locally advanced, unresectable or metastatic BRAFV600-mutant melanoma were randomised to receive encorafenib 450 mg once daily plus binimetinib 45 mg twice daily, encorafenib 300 mg once daily or vemurafenib 960 mg twice daily. Adverse events that represent known effects of available BRAFi and/or MEKi were evaluated. RESULTS: The safety population included a total of 570 patients (encorafenib+binimetinib = 192; encorafenib = 192; vemurafenib = 186). Median duration of exposure was longer with encorafenib+binimetinib (51 weeks) than with encorafenib (31 weeks) or vemurafenib (27 weeks). Common BRAFi/MEKi toxicities with encorafenib+binimetinib were generally manageable, reversible and infrequently associated with discontinuation. Pyrexia was less frequent with encorafenib+binimetinib (18%) and encorafenib (16%) than with vemurafenib (30%) and occurred later in the course of therapy with encorafenib+binimetinib (median time to first onset: 85 days versus 2.5 days and 19 days, respectively). The incidence of photosensitivity was lower with encorafenib+binimetinib (5%) and encorafenib (4%) than with vemurafenib (30%). The incidence of serous retinopathy was higher with encorafenib+binimetinib (20%) than with encorafenib (2%) or vemurafenib (2%), but no patients discontinued encorafenib+binimetinib because of this event. CONCLUSION: Encorafenib+binimetinib is generally well tolerated and has a low discontinuation rate in patients with BRAFV600-mutant melanoma, with a distinct safety profile as compared with other anti-BRAF/MEK targeted therapies. TRIAL REGISTRATION: ClinicalTrials.gov (Identifier: NCT01909453) and with EudraCT (number 2013-001176-38).
引用
- Gogas HJ, Flaherty KT, Dummer R, et al. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. Eur J Cancer. 2019. PMID: 31437754. doi:10.1016/j.ejca.2019.07.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。